Bilal  Arif net worth and biography

Bilal Arif Biography and Net Worth

EVP, Chief Technical Operations Officer of Sarepta Therapeutics

Bilal Arif joined Sarepta in 2019 as senior vice president, head of strategy and technical operations where he was central in helping grow the technical operations team and building the Company’s manufacturing capabilities. He was named chief technical operations officer in December 2022. As head of technical operations, Bilal is responsible for the Company’s CMC strategy and global supply chain management for its RNA and gene therapy portfolio.

Having dedicated his entire career to the strategic and operational aspects of manufacturing, Bilal is a well-regarded and recognized leader with over 20 years of relevant biotech, pharma and management experience, including serving as vice president, product strategy & planning, technical operations at Shire. During his tenure at Shire, Bilal served as a member of the technical operations leadership team. His experience spans across supporting early clinical-stage programs through to market authorization. At Shire, Bilal was also responsible for leading the TechOps team responsible for conducting due diligence/integration of new technologies and M&A assets.

“My interest in manufacturing and technical operations is matched by my desire to be a part of the most exciting and promising areas of scientific innovation, which was the primary driver for joining Sarepta. I love the pace, which supports the idea that we are truly dragging tomorrow into today for patients. For these reasons and many more, being at Sarepta in this role and at this time, has been and continues to be a real highlight of my career.”

In touching upon his vision for Sarepta’s CMC strategy, Bilal cited proactive management, preparedness, quick decision making, and recognizing the importance of teamwork as being a promising formula for success.

“Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team.” 

Bilal received his Bachelor of Engineering degree in chemical engineering from McGill University, a Master of Science in Biotechnology from Tufts University, and an MBA from Brown University’/Instituto de Empresa (IE) Business School.  

What is Bilal Arif's net worth?

The estimated net worth of Bilal Arif is at least $2.56 million as of June 24th, 2024. Mr. Arif owns 21,261 shares of Sarepta Therapeutics stock worth more than $2,559,824 as of October 6th. This net worth evaluation does not reflect any other investments that Mr. Arif may own. Learn More about Bilal Arif's net worth.

How old is Bilal Arif?

Mr. Arif is currently 52 years old. There are 4 older executives and no younger executives at Sarepta Therapeutics. The oldest executive at Sarepta Therapeutics is Mr. Douglas S. Ingram Esq., President, CEO & Director, who is 61 years old. Learn More on Bilal Arif's age.

How do I contact Bilal Arif?

The corporate mailing address for Mr. Arif and other Sarepta Therapeutics executives is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. Sarepta Therapeutics can also be reached via phone at (617) 274-4000 and via email at [email protected]. Learn More on Bilal Arif's contact information.

Has Bilal Arif been buying or selling shares of Sarepta Therapeutics?

Bilal Arif has not been actively trading shares of Sarepta Therapeutics within the last three months. Most recently, Bilal Arif sold 7,859 shares of the business's stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a transaction totalling $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares of the company's stock, valued at $3,467,243.88. Learn More on Bilal Arif's trading history.

Who are Sarepta Therapeutics' active insiders?

Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.

Are insiders buying or selling shares of Sarepta Therapeutics?

In the last twelve months, Sarepta Therapeutics insiders bought shares 3 times. They purchased a total of 112,263 shares worth more than $10,898,040.40. In the last twelve months, insiders at the biotechnology company sold shares 9 times. They sold a total of 78,532 shares worth more than $11,647,905.42. The most recent insider tranaction occured on August, 30th when CFO Ian Michael Estepan sold 5,985 shares worth more than $822,099.60. Insiders at Sarepta Therapeutics own 7.7% of the company. Learn More about insider trades at Sarepta Therapeutics.

Information on this page was last updated on 8/30/2024.

Bilal Arif Insider Trading History at Sarepta Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/24/2024Sell7,859$163.08$1,281,645.7221,261View SEC Filing Icon  
3/1/2024Sell2,000$128.84$257,680.0026,836View SEC Filing Icon  
See Full Table

Bilal Arif Buying and Selling Activity at Sarepta Therapeutics

This chart shows Bilal Arif's buying and selling at Sarepta Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sarepta Therapeutics Company Overview

Sarepta Therapeutics logo
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $120.40
Low: $118.63
High: $121.88

50 Day Range

MA: $132.53
Low: $118.76
High: $146.03

2 Week Range

Now: $120.40
Low: $55.25
High: $173.25

Volume

893,683 shs

Average Volume

1,277,662 shs

Market Capitalization

$11.38 billion

P/E Ratio

1,094.55

Dividend Yield

N/A

Beta

0.82